

Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders

著者	Kaneko Yoshibumi, Miyajima Hiroaki, Piperno Alberto, Tomosugi Naohisa, Hayashi Hisao, Morotomi Natsuko, Tsuchida Ken-ichi, Ikeda Takaaki, Ishikawa Akihisa, Ota Yusuke, Wakusawa Shinya, Yoshioka Kentaro, Kono Satoshi, Pelucchi Sara, Hattori Ai, Tatsumi Yasuaki, Okada Toshihide, Yamagishi Masakazu
journal or publication title	Journal of Gastroenterology
volume	45
number	11
page range	1163-1171
year	2010-11-01
URL	http://hdl.handle.net/2297/26279

doi: 10.1007/s00535-010-0259-8

Original Article

Title:

Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders

Short title:

Hepcidin in iron overload syndromes

Authors:

Yoshibumi Kaneko¹, Hiroaki Miyajima², Alberto Piperno³, Naohisa Tomosugi⁴, Hisao Hayashi⁵, Natsuko Morotomi⁶, Ken-ichi Tsuchida⁷, Takaaki Ikeda⁸, Akihisa Ishikawa⁹, Yusuke Ota¹⁰, Shinya Wakusawa¹¹, Kentaro Yoshioka¹², Satoshi Kono², Sara Pelucchi³, Ai Hattori⁵, Yasuaki Tatsumi⁵, Toshihide Okada¹, Masakazu Yamagishi¹

Affiliations:

¹Department of Internal Medicine, Graduate School of Medicine, Kanazawa University

²First Department of Medicine, Hamamatsu University School of Medicine

³Department of Clinical Medicine and Prevention, University of Milano-Bicocca

⁴Division of Nephrology, Department of Internal Medicine, Kanazawa Medical University

⁵Department of Medicine, Aichi Gakuin University School of Pharmacy

⁶Department of Internal Medicine, Kitakyushu Municipal Moji Hospital

⁷Department of Internal Medicine, Manda Memorial Hospital

⁸Department of Internal Medicine, Yokosuka Kyousai Hospital

⁹Department of Gastroenterology, Hitachi General Hospital

¹⁰Department of Rheumatology, Minami-Okayama Medical Center

¹¹Medical Technology of Health Sciences, Nagoya University School of Medicine

¹²Department of Gastroenterology, Fujita Health University Hospital

Details of the corresponding author:

Yoshibumi Kaneko, M.D.

Department of Internal Medicine, Graduate School of Medicine Kanazawa University,
13-1 Takara-Machi, Kanazawa City, Ishikawa, Japan

Telephone no.: +81-76-265-2255, Fax no.: +81-76-234-4251

E-mail address: mdyoshi@arion.ocn.ne.jp

Electronic word count (excluding abstract and references): 3,162 words

Number of figures and tables: 3 figures and 2 tables

Abstract

Background. Iron overload syndromes include a wide spectrum of genetic and acquired conditions. Recent studies suggest suppressed hepcidin synthesis in the liver to be the molecular basis of hemochromatosis. However, a liver with acquired iron overload synthesizes an adequate amount of hepcidin. Thus, hepcidin could function as a biochemical marker for differential diagnosis of iron overload syndromes.

Methods. We measured serum iron parameters and hepcidin-25 levels followed by sequencing *HFE*, *HJV*, *HAMP*, *TFR2*, and *SLC40A1* genes in 13 Japanese patients with iron overload syndromes. In addition, we performed direct measurement of serum hepcidin-25 levels using liquid chromatography–tandem mass spectrometry in 3 Japanese patients with aceruloplasminemia and 4 Italians with *HFE*-hemochromatosis.

Results. One patient with *HJV*-hemochromatosis, 2 with *TFR2*-hemochromatosis, and 3 with ferroportin disease were found among the 13 Japanese patients. The remaining 7 Japanese patients showed no evidence for genetic basis of iron overload syndrome. As far as the serum hepcidin-25 was concerned, seven patients with hemochromatosis and 3 with aceruloplasminemia showed markedly decreased serum hepcidin-25 levels. In contrast, 3 patients with ferroportin disease and 7 with secondary iron overload syndromes showed serum hepcidin levels parallel to their hyperferritinemia. Patients with iron overload syndromes were divided into 2 phenotypes presenting as low and high hepcidinemia. These were then associated with their genotypes.

Conclusion. Determining serum hepcidin-25 levels may aid differential diagnosis of iron overload syndromes prior to genetic analysis. (231 words)

Key Words: hepcidin, ceruloplasmin, hemochromatosis

Introduction

Hemochromatosis is caused by inadequate iron absorption leading to excessive body iron stores. If left undetected and untreated, progressive iron overload may independently lead to cirrhosis, diabetes mellitus (DM), cardiac failure, and endocrine disorders. Hemochromatosis includes HFE-hemochromatosis mainly from the C282Y/C282Y mutation in *HFE*.¹ Non-HFE hemochromatosis is associated with the hemojuvelin (*HJV*),² human antimicrobial peptide (*HAMP*),³ and transferrin receptor 2 (*TFR2*)⁴ genes. Evidence suggests the crucial role played by the hormone hepcidin, encoded by *HAMP*, in hemochromatosis. Hepcidin was first identified as an antimicrobial peptide synthesized in the liver and excreted in the urine.^{5,6} Subsequent animal model studies indicated a close association of hepcidin with iron overload.^{7,8} Hepcidin forms a complex with the transmembrane iron exporter protein of ferroportin; the complex is then internalized, and degraded in reticuloendothelial cells and enterocytes.⁹ Thus, hepcidin regulates body iron levels by functionally suppressing ferroportin. Pathological inflammation also increases hepcidin synthesis,^{8,10} while erythropoietic activity decreases it.¹¹ However, regardless of body iron overload, hepcidin mRNA expression in the liver is suppressed in patients with hemochromatosis,¹² resulted in decreased urinary output of hepcidin.^{2,13,14} Evidence suggests that functional disruption of the hepcidin system might be a molecular basis for hemochromatosis, but few reports on the active form of serum hepcidin-25 have been published to date owing to the lack of reliable methods for quantitative determination.^{15,16,17}

Aceruloplasminemia is a neurological disorder characterized by heavy iron overload in the liver and brain with clinical manifestations of ataxia, involuntary movement, retinal degeneration, and dementia around the age of 50.¹⁸ It results from a mutation in the ceruloplasmin gene (*CP*).¹⁹ Ceruloplasmin encoded by *CP* is a major ferroxidase in circulation,

and is believed to play a crucial role in maintaining stability of cell surface ferroportin.²⁰ Impaired regulation of ceruloplasmin negatively impacts ferroportin expression, which in turn blocks iron transport in patients.

Ferroportin disease has been recently identified as a genetic iron overload syndrome. The disease is inherited as an autosomal dominant trait,^{21, 22} and occurs in populations throughout the world.^{23, 24, 25} Patients with a major form of ferroportin disease (type A) present with macrophage iron deposition and high ferritin levels despite normal transferrin saturation.^{21, 22} In contrast, patients with the minor form (type B) develop abnormalities, such as elevated transferrin saturation and a more severe, mixed iron overload in parenchymal and reticuloendothelial cells similar to typical hemochromatosis.^{23, 26} It is interesting that the urinary output of hepcidin increases in type A²⁷ and is normal in type B ferroportin disease.²⁸

Transfusions and parenteral iron supplements are relatively frequent causes of secondary iron overload in patients with refractory anemia. Before the clinical introduction of erythropoietin, the anemia associated with chronic renal failure (CRF) was treated with transfusions or inadequate iron supplements leading to a variety of hyperferritinemias.²⁹ Patients with chronic hepatitis C (CHC) may also face complications with parenchymal cell iron overload in the liver.³⁰ Iron overload is frequently observed in patients with alcoholic liver disease (ALD) or nonalcoholic steatohepatitis (NASH).³¹ Thus, some patients with anemia, CRF, CHC, ALD, and NASH present with hyperferritinemia and liver iron deposition mimicking hemochromatosis and hence, require a differential diagnosis from genetic iron overload conditions. The liver with acquired iron overload can synthesize an appropriate amount of hepcidin. Therefore, direct measurement of serum hepcidin-25 levels could differentiate acquired iron overload from its genetic form, and also confirm results from current investigations, which are based on either

hepcidin mRNA expression in the liver or urinary output of hepcidin. Of the 3 types of hepcidin molecules, namely hepcidins-20, -22, and -25, the active form that binds to ferroportin is hepcidin-25.³² In this study, we evaluated serum hepcidin-25 levels as a biochemical marker to differentiate among iron overload disorders in 20 patients with established genetic basis of iron overload syndrome.

Methods

Twenty patients were enrolled in this study and were divided into 3 groups. The first group comprised of 13 Japanese patients who were referred to 2 institutes in central Japan (Kanazawa University Hospital and Aichi Gakuin University) between January 1998 and December 2009 for a genetic study of patients with iron overload syndromes. The second group comprised of 3 Japanese patients with aceruloplasminemia. Their condition had been effectively managed post diagnosis at Hamamatsu University Hospital. The clinical diagnosis of the 3 patients with aceruloplasminemia was confirmed by gene analyses for *CP*¹⁹ as per procedures approved by the ethics committees of Hamamatsu University (No. HUH 21-91) before the entry time of February of 2008 for direct determination of serum hepcidin-25. The third group comprised 4 of Italian patients who were randomly selected from an HFE hemochromatosis database at the University of Milano–Bicocca. All patients gave their informed written consent to genetic testing, measurement of all biochemical markers including serum hepcidine-25 levels and treatment according to the Declaration of Helsinki.

A biochemical study including determination of serum hepcidin-25 levels as well as a genetic analysis (prediagnostic fresh sampling) were performed in the first group of patients. The inclusion criterion was a biochemical iron overload twice as high as the normal range for serum ferritin levels (normal for male: 26–310 ng/mL; females: 7–110 ng/mL). The exclusion criterion was anemia less than 11.0 g/dL. Other biochemical tests included the measuring hemoglobin, serum iron levels, and iron-binding capacity. Transferrin saturation was estimated by the standard method: serum iron ($\mu\text{g/dL}$)/iron-binding capacity ($\mu\text{g/dL}$) multiplied by 100.

The genes analyzed in the first group of patients included *HFE*, *TFR2*, *HJV*, *HAMP*, and *SLC40A1*.^{25, 33, 34} Informed consent was obtained from each patient, and the protocol was

approved by the ethics committees of 2 institutes (Kanazawa University Hospital, No. 2004-66; and Aichi Gakuin University, Nos. 6 and 8). And the protocol was approved by the ethics committees of 2 institutes (Kanazawa University Hospital, No. 2004-66; and Aichi Gakuin University, Nos. 6 and 8).

In aceruloplasminemia patients, fresh sera for measuring serum hepcidin-25 levels were sampled between January and February 2008, during the post diagnosis management period. Iron overload persisted in these patients because of intolerance to phlebotomy treatment (fresh sampling during treatment). Long-term frozen sera obtained from the third group of Italian patients during the pre- and post-treatment periods were sent from Italy to an institute in Japan in February 2008 followed by measuring serum hepcidin-25 levels (long-term frozen sera).

Biochemical variables including serum hepcidin-25 levels were determined during phlebotomy treatment in 4 patients (cases 3, 5, 18, and 20).

Quantification of serum hepcidin-25 by LC tandem MS.

Sera from all patients were frozen and stored at -80°C until analysis. Serum hepcidin-25 levels were determined using a liquid chromatography–tandem mass spectrometry-based assay system.^{35, 36} Rat serum spiked with human synthetic hepcidin-25 (MW2789, Peptide Inc., Minoh-shi, Japan) was used to obtain 1, 2, 4, 8, 16, 32, 64, and 128 ng/mL standards. Synthetic isotopic human hepcidin-25 (MW2830; Peptide Institute) was added to each diluted sample and to the standards as an internal standard. The samples and standards were then injected onto a 150×2.1 mm PLRP-S column packed with 5-mm particles with a 300-Å pore size (Varian Inc., CA, USA) for LC (Prominence LC20-ADvp; Shimadzu, Kyoto, Japan). The column eluent was connected to an ion spray source on a hybrid triple-quadrupole

linear ion trap system (400 QTRAP LC/MS/MS System; Applied Biosystems, Foster City, CA, USA). A standard curve was generated to determine the mass spectrometer response for human synthetic hepcidin-25 under the described assay conditions. The curve was found to be linear from 1.0 to 128 ng/mL, ($y = 0.008x + 0.002$, $r = 0.998$). Intraassay and interassay CVs were <6.7% and <8.8%, respectively. The lower limit of detection was 1.0 ng/mL with a signal to noise ratio of 10:1.

Statistical analysis

All pretreatment biochemical data were expressed as mean \pm SD. Statistical analysis was performed using the nonparametric test (Spearman's rank method) to determine the strength of a correlation between serum ferritin and serum hepcidin-25 level.

Results

Patient profiles and laboratory data at entry are indicated in Table 1. The serum ferritin levels were 2680 ± 2595 ng/mL (range, 635–10,191 ng/mL), whereas transferrin saturation ranged from 11.2 to 99.0% as severity of aceruloplasminemia corresponded with the severity of iron deficiency. Five patients, including those with aceruloplasminemia, were mildly anemic despite the iron overload. One of the 15 patients who had undergone a liver biopsy had exceptional liver histology, which was almost normal in structure and showed minimal iron overload in the Kupffer cells (Case 11). Six patients (Cases 1–4, 6, 7) had advanced fibrosis or cirrhosis associated with parenchymal or mixed iron overload of hepatocytes and Kupffer cells. In contrast to heavy iron deposits, one patient (Case 13) had mild portal fibrosis and 3 patients (Cases 8–10) were free from fibrosis in the liver. In addition, 8 patients had DM, while only 1 patient had a triad of hemochromatosis of cirrhosis, DM, and pigmentation.

The results of the genetic study, serum hepcidin-25 levels, and final diagnoses of the iron overload syndromes are summarized in Table 2. The patients with iron overload syndromes were divided into 2 groups. Ten patients had serum hepcidin-25 levels below the upper limit of the normal range of 20 ng/mL (low group; Cases 1–10),^{35, 36, 50} while 10 patients had a level higher than 40 ng/mL (high group; Cases 11–20). A statistically significant difference between the low and high hepcidin groups was also observed (7.4 ± 5.8 vs 138.6 ± 62.6 ng/mL; $P < 0.01$: Mann–Whitney test). This grouping was supported by another parameter of hepcidin/ferritin ratio that could be an iron regulatory hormone index adjusted by the representative body iron stores. The indices ranged between 0.05 and 16.0×10^{-3} in the low hepcidin group, and between 19.6 and 148.8×10^{-3} in the high hepcidin group. The low hepcidin group included 3 Japanese (Cases 1–3) and 4 Italian (Cases 4–7) patients with non-HFE and HFE hemochromatosis,

respectively. Three Japanese aceruloplasminemic patients (Cases 8–10) had low serum hepcidin-25 levels similar to those found in hemochromatosis.

The high hepcidin group included 2 families with ferroportin types A and B, respectively. The 49-year-old proband (Case 11) who exhibited selective iron overload in the reticuloendothelial cells, had a serum hepcidin-25 level of 42.5 ng/mL, while his 81-year-old father (Case 12) had a serum hepcidin-25 level of 155 ng/mL comparable with his high ferritin level of 2636 ng/mL. Another 66-year-old male patient (Case 13) of the second ferroportin disease family exhibited marked iron overload in the liver, which was first detected by CT imaging and later confirmed as heavy, mixed type-iron overload by biopsy. His serum hepcidin-25 level was 156.7 ng/mL and his serum ferritin level was also high (7980 ng/mL) with 89.2% transferrin saturation. The remaining 7 patients in the high hepcidin group had a variety of iron overload syndromes. One patient with CRF and DM (Case 14) and 3 patients with CHC (Cases 15–17) showed high serum hepcidin-25 levels corresponding to the biochemical iron markers. Mild iron overload associated with a high serum hepcidin-25 level was found in a patient with ALD (Case 19). Two patients (Cases 16 and 20) with a history of repeated use of iron supplements also had high serum hepcidin-25 levels. The *HFE*, *HJV*, *HAMP*, *TFR2*, and *SLC40A1* analyses on these 7 patients excluded a genetic basis for their iron overloads; therefore, we concluded that they all had acquired iron overload liver diseases.

As shown in Figure 1, iron overload syndromes were clearly divided into two groups, but no correlations were observed between serum ferritin and hepcidin-25 levels in the high hepcidin group ($p=0.096$), nor low hepcidin group ($p=0.349$). Serum ferritin levels presented in a wide range (885–10,191 ng/mL), while all serum hepcidin-25 levels were below 20 ng/mL in the low hepcidin group. In contrast, both serum ferritin levels and hepcidin-25 levels in the high

hepcidin group presented in wide ranges of 635–7,980 ng/mL and 42.5–238.7 ng/mL, respectively.

Responses to serum hepcidin-25 to iron removal by phlebotomy are indicated in Figure 2. All patients responded similarly to the treatment, but differed in their serum hepcidin-25 levels. In 2 patients with TFR2 (Case 3) and HFE hemochromatosis (Case 5), pretreatment serum hepcidin-25 levels were low and declined slightly after treatment. In contrast, pretreatment serum hepcidin-25 levels were high and showed a marked reduction after treatment in the other 2 patients with secondary iron overload syndromes (Cases 18 and 20).

Discussion

This is the first report describing serum hepcidin-25 levels in patients with a variety of iron overload syndromes to the best of our knowledge. Because genetic iron overload syndromes showed an ethnic difference with regard to prevalence,^{19, 37, 38} the patient population was intentionally expanded to a wider range than the general population. Four Italian patients with HFE hemochromatosis and 3 Japanese patients with aceruloplasminemia were included in the study with 13 Japanese patients with a variety of iron overload syndromes referred to 2 institutes in central Japan. Patients with chronic inflammations such as CRF, CHC, and rheumatoid arthritis as well as patients with mild anemia who were on iron supplements were included. However, patients with severe anemia and acute phase inflammation were excluded from the study because hepcidin synthesis is decreased by erythropoietic activity and increased by acute inflammation.^{8, 11}

Although this study with its small sample size appears preliminary, the iron overload syndromes in patients could still be divided into 2 phenotypes, one with high and the other with low hepcidinemia, both closely linked to their respective genotype; this information may thus be crucial prior to performing genetic analysis. This study suggests that low hepcidin groups include individuals with hemochromatosis and aceruloplasminemia, while high hepcidin groups include those with ferroportin disease and secondary iron overload syndromes. Hemoglobin, serum ferritin levels, and iron saturation of transferrin have their limitations as grouping variables for iron overload syndromes. The direct measurement of serum hepcidin-25 levels are consistent with the suppressed expression of hepcidin mRNA in the livers of patients with HFE hemochromatosis¹² and measurements of the urinary output of hepcidin in patients with HJV hemochromatosis² as well as TFR2 hemochromatosis.¹⁴ HAMP hemochromatosis could also be

classified in this group on detecting decreased urinary output of hepcidin in such patients.¹³ Inadequate serum hepcidin levels and a response to phlebotomy similar to that observed in this study were reported for HFE hemochromatosis recently.¹⁶

This is the first study of its kind to demonstrate low serum hepcidin-25 levels in patients with aceruloplasminemia. Similar presentations resulting from body iron overload, such as low hepcidin synthesis in the liver and low transferrin saturation are reported in ceruloplasmin knockout mice.³⁹ Ceruloplasmin is a multicopper oxidase and plays a role in the mobilization and oxidation of iron from tissue stores with subsequent incorporation of ferric iron into transferrin.^{18, 19, 20} According to the iron sensor hypothesis of TFR2, increasing concentrations of iron-saturated transferrin increase TFR2 protein levels in hepatocyte by protecting the receptor from degradation. And consecutively, TFR2 would be expected to increase the association with HFE and to stimulate of hepcidin transcription.^{40, 41} This hypothesis suggests a crucial role of low iron saturation of transferrin in falsely signaling iron deficiency to the liver in patients with aceruloplasminemia. This results in suppressed synthesis and secretion of hepcidin into blood. Further studies are needed to clarify the involvement of a low-set hepcidin system in increased iron absorption in the gut of patients with aceruloplasminemia.

Serum hepcidin appears to be regulated at a higher level in patients with acquired iron overload syndromes than in the hemochromatosis group. Serum hepcidin levels were also adequately controlled in our patients with ferroportin disease type A and B. Age-dependent iron overload in the type A proband and his father (Cases 11 and 12) was associated with greater hyperhepcidinemia. These blood test results were consistent with findings in previous reports that measured urinary output of hepcidin.²⁷ Serum hepcidin was 156.7 ng/mL in another patient (Case 13) whose liver histology was compatible with type B ferroportin disease. In patients with

type A disease, *SLC40A1* mutations generate a protein that is defective in cell surface expression or loss of iron export function.^{42, 43, 44} In the less prevalent type B, the mutant gene generates proteins that show normal cell surface expression but reduced sensitivity to hepcidin.^{42, 43} The resistance of ferroportin to hepcidin might be the key not only to the iron overload of ferroportin disease, but also to the secondary iron overload syndromes. In fact, only 2 of the 7 patients had a history of repeated use of iron supplements followed by adequate hepcidin regulation. The increased serum hepcidin-25 levels appeared to have suppressed iron absorption in the gut. In patients with chronic diseases of the kidney, liver, and joints, the current state of hyperhepcidinemia might be induced by an iron overload and chronic inflammation, but the pathophysiologic processes leading to body iron accumulation during the long-term disease condition remain to be elucidated. Ferroportin proteins in the secondary iron overload syndromes may also be resistant to hepcidin, permitting persistent iron absorption in the gut.

The involvement of the hepcidin system in iron regulation in CHC patients was unclear and thus much debated.^{15, 17, 45, 46} Three of our patients coinfecting with HCV had a hepcidin-resistant iron overload syndrome without the evidence of a genetic basis for the latter. Establishing the serum hepcidin-25 levels^{35, 36, 47} might clarify complex issues related to ferroportin disease and the secondary iron overload syndromes.

The pregenetic differential analysis of patients with iron overload syndromes should include the evaluation of ferritin, ceruloplasmin, and hepcidin-25 as 3 potential biochemical markers (Figure. 3). The first test should ideally determine serum ferritin levels. Then, the serum hepcidin-25 levels provide a guideline for a genetic study. Serum ceruloplasmin should be determined in the low hepcidin group to rule out a rare genetic disease with aceruloplasminemia. Aceruloplasminemia itself might be diagnostic, and further studies on hypohepcidinemia might

indicate a lifelong low-iron diet in either symptomatic or presymptomatic patients because of their intolerance of iron reduction therapy.⁴⁸ For patients without aceruloplasminemia, gene analysis for hemochromatosis is highly recommended to confirm their genetic background. The primary target gene in Caucasians is *HFE*^{1,37} and the secondary genes include *TFR2*, *HJV*, and *HAMP*. However, the primary target gene for non-Caucasians would be *TFR2*^{33,49} followed by *HJV*, *HAMP*, and *HFE* because HFE hemochromatosis is rarely present in other ethnic groups.³⁷

As noted in our patients, a high regulatory hepcidin set-point suggests a diagnosis of ferroportin disease. Before final diagnosis of a secondary iron overload syndrome, genetic analysis of *SLC40A1* is required. Without such a genetic study it is difficult to rule out the possible complication of this rare genetic disease with the more common, acquired iron overload syndromes.

In conclusion, measurement of the serum hepcidin-25 levels has the potential for grouping patients with iron overload syndromes based on a newly proposed iron regulatory system. When combined with ferritin and ceruloplasmin levels, hepcidin-25 levels could be a potential test for the diagnosis of hemochromatosis and related disorders.

References

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996;13:399–408.
2. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dubé MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. *Nat Genet* 2004;36:77–82.
3. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial hepcidin is associated with severe juvenile hemochromatosis. *Nat Genet* 2003;33:21–2.
4. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. *Nat Genet* 2000;25:14–5.
5. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1,

a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett* 2000;480:147–50.

6. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem* 2001;276:7806–10.
7. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proc Natl Acad Sci USA* 2001;98:8780–5.
8. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem* 2001;276:7811–9.
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004;306:2090–3.
10. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of

inflammation, is a type II acute-phase protein. *Blood* 2003;101:2461–3.

11. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood* 2006;108:3730–5.
12. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. *Lancet* 2003;361:669–73.
13. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. *Blood* 2005;105:4103–5.
14. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. *Blood* 2005;105:1803–6.
15. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. *J Hepatol* 2008;49:702–10.
16. van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJ, Janssen MC, et al.

Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. *Br J Haematol* 2008;142(6):979–85.

17. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. *J Hepatol* 2009;51:845–52.
18. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. *Neurology* 1987;37:761–7.
19. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RTA, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. *Proc Natl Acad Sci USA* 1995;92:2539–43.
20. de Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmine. *EMBO J* 2007; 26:2823–31.

21. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. *Nat Genet* 2001;28:213–4.
22. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. *J Clin Invest* 2001;108:619–23.
23. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loreal O, Fergelot P, Delacour T, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. *J Hepatol* 2003;39:286–9.
24. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. *Blood Cells Mol Dis* 2003;31:305–9.
25. Koyama C, Wakusawa S, Hayashi H, Ueno T, Suzuki R, Yano M, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia

- associated with a relatively low transferrin saturation of iron. *Intern Med* 2005;44:990–3.
26. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. *Haematologica* 2003;88:824–6.
27. Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. *Hepatology* 2005;42:466–2.
28. Cemonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, et al. Genetic and clinical heterogeneity of ferroportin disease. *Br J Haematol* 2005;131:663–70.
29. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? *Clin J Am Soc Nephrol* 2006;Suppl 1:S9–18.
30. Bonkovsky H, Banner BF, Rothman AL. Iron and chronic viral hepatitis. *Hepatology*

1997;25:759–68.

- 31 Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. *World J Gastroenterol* 2007;13:4699–707.
32. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. *J Biol Chem* 2002;277:37597–603.
33. Koyama C, Wakusawa S, Hayashi H, Suzuki R, Yano M, Yoshioka K, et al. Two novel mutations, L490R and V561X, in the transferrin receptor 2 in Japanese patients with hemochromatosis. *Haematologica* 2005;90:302–7.
34. Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. *J Hepatol* 2005;43:740–2.
35. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification

- of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. *Rapid Commun Mass Spectrom* 2007;21:4033-8.
36. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. *Blood* 2007;110:1048-54.
37. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. *J Med Genet* 1997;34:275-8.
38. Lok CY, Merryweather-Clarke AT, Viprakasit V, Chinthammitr Y, Srichairatanakool S, Limwongse C, et al. Iron overload in the Asian community. *Blood* 2009;114(1):20-5.
39. Guo P, Cui R, Chang YZ, Wu WS, Qian ZM. Hepcidin, an antimicrobial peptide is down regulated in ceruloplasmin-deficient mice. *Peptides* 2009;30:262-6.
40. Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. *Blood* 2004;104:4287-93.

41. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. *Blood* 2004;104:4294–9.
42. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, et al. The molecular basis of ferroportin-linked hemochromatosis. *Proc Natl Acad Sci USA* 2005;102(25):8955–60.
43. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. *Blood* 2005;106(3):1092–7.
44. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. *Blood* 2005;105(10):4096–102.
45. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepatic mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. *J Clin Gastroenterol* 2005;39:71–4.

46. Lin TJ, Liao LY, Chou JM, Liu SO, Wang CK. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients. *Hepatogastroenterology* 2009;56:1146–51.
47. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. *Blood* 2008;112:4292–7.
48. Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. *Gut* 2004;53:756–8.
49. Hattori A, Wakusawa S, Hayashi H, Harashima A, Sanae F, Kawanaka M, et al. AVAQ 594-597 deletion of the TFR2 gene in a Japanese family with hemochromatosis. *Hepatol Res* 2003;26:154–5
50. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. *Haematologica* 2008;93:1550–4.

Table 1. The Clinical Features and Laboratory Data of Patients with Iron Overload Syndromes at Entry

Pt.	Age/Sex	Clinical Diagnosis	Blood Tests			Liver Histology /Iron Deposits	DM	Skin Pigmentation
			s-Ferritin (ng/mL)	Transferrin Saturation (%)	Hb (g/dL)			
1* ¹	48/M	HJV-hemochromatosis	6115	94.8	15.8	cirrhosis/P	yes	yes
2* ²	49/M	TFR2-hemochromatosis	1057	93.5	13.8	fibrosis/P	yes	no
3	40/M	hemochromatosis	10191	94.2	14.0	fibrosis/mixed	yes	no
4* ³	55/M	HFE-hemochromatosis	2141	94.0	15.6	cirrhosis/mixed	no	no
5* ³	33/M	HFE-hemochromatosis	1821	92.0	13.8	chronic hepatitis/mixed	no	no
6* ³	65/F	HFE-hemochromatosis	2204	87.0	15.2	cirrhosis/mixed	no	yes
7* ³	43/M	HFE-hemochromatosis	3268	88.0	16.2	cirrhosis/mixed	no	yes
8* ⁴	59/F	aceruloplasminemia	885	11.2	10.2	normal/mixed	yes	no
9* ⁴	55/F	aceruloplasminemia	1035	14.6	9.4	normal/mixed	yes	no
10* ⁴	62/M	aceruloplasminemia	1140	12.0	8.9	normal/mixed	yes	no
11* ⁵	49/M	ferroportin disease type A	696	28.6	14.4	normal/RE	no	no
12* ⁵	81/M	ferroportin disease type A	2636	88.3	13.4	no biopsy	no	no
13	66/M	hemochromatosis	7980	89.3	14.1	mild fibrosis/mixed	yes	no
14	85/M	CRF	1558	73.6	12.5	no biopsy	yes	no
15	50/M	CHC	635	95.5	14.3	chronic hepatitis/P	no	no
16	42/F	CHC and ISA	1270	50.8	11.1	no biopsy	no	no
17	58/F	CR of CHC to IFN	1721	61.8	13.8	chronic hepatitis/P	no	no
18	60/F	RA, hemochromatosis	4378	91.2	11.7	no biopsy	no	no
19	64/M	alcoholic cirrhosis	799	99.0	15.6	no biopsy	no	no
20	33/F	ISA	2076	91.1	12.6	normal/P	no	no
Subtotal from Pt.1 to 10 (Mean±SD)			2986±2978	68.1±38.4	13.3±2.8			
Subtotal from Pt.11 to 20 (Mean±SD)			2375±2266	76.9±23.0	13.4±1.4			
Total (Mean±SD)			2680±2595	72.5±31.2	13.3±2.1			

*¹ Genetic study of the patient was reported in detail.³⁰

*² Genetic study of the patient was reported in detail.²⁹

*³ Italian patient with HFE-hemochromatosis specially enrolled

*⁴ Japanese patient with aceruloplasminemia specially enrolled

*⁵ Genetic study of the patient was reported in detail.¹⁸

Normal value of serum ferritin; male:26-310 ng/mL, female:7-110 ng/mL

Normal value of transferrin saturation; 40-70%

Normal value of hemoglobin; male:13.5-17.0 g/dL, female:11.2-14.5 ng/mL

DM; diabetes mellitus

M; male, F; female

P; parenchymal, RE; reticuloendothelial, mixed; parenchymal and reticuloendothelial

CRF; chronic renal failure

ISA; iron supplement for anemia of unknown etiology

CHC; chronic hepatitis C

CR; complete responder

IFN; interferon

RA; rheumatoid arthritis

Table 2. Results of Genetic Study, Serum Hepcidin Determination, and Final Diagnosis for Iron Overload Syndromes

Pt.	Genetic Study	Serum Hepcidin-25 (ng/mL)	Hepcidin-25/Ferritin ($\times 10^{-3}$)	Final Diagnosis for Iron Overload Syndrome
1	745G>C/745G>C in <i>HJV</i> * ¹	0.3	0.05	HJV-hemochromatosis
2	1469T>G/1469T>G in <i>TFR2</i> * ²	2.8	2.7	TFR2-hemochromatosis
3	1100T>G/2008-9delAC in <i>TFR2</i> * ³	12.2	1.2	TFR2-hemochromatosis
4	845G>A/845G>A in <i>HFE</i> * ⁴	3.0	1.4	HFE-hemochromatosis
5	845G>A/845G>A in <i>HFE</i>	6.7	3.6	HFE-hemochromatosis
6	845G>A/845G>A in <i>HFE</i>	4.1	1.9	HFE-hemochromatosis
7	845G>A/845G>A in <i>HFE</i>	3.1	1.0	HFE-hemochromatosis
8	607Ains/607Ains in <i>Cp</i>	10.3	11.6	aceruloplasminemia
9	2630G>A/2630G>A in <i>Cp</i> * ⁵	13.1	12.7	aceruloplasminemia
10	1287TACACins/1287TACACins in <i>Cp</i>	18.2	16.0	aceruloplasminemia
11	1467A>C/wt in <i>SLC40A1</i> * ⁶	42.5	61.1	ferroportin disease type A
12	1467A>C/wt in <i>SLC40A1</i>	155.0	58.8	ferroportin disease type A
13	470A>C/wt in <i>SLC40A1</i> * ⁷	156.7	19.6	ferroportin disease type B
14	no mutations responsible	181.0	116.2	2 nd iron overload in CRF and DM
15	no mutations responsible	63.0	99.2	2 nd iron overload in CHC
16	no mutations responsible	189.0	148.8	2 nd iron overload in CHC with iron supplement
17	no mutations responsible	82.5	47.9	2 nd iron overload in CHC
18	no mutations responsible	238.7	54.5	2 nd iron overload in RA
19	no mutations responsible	105.5	132.0	2 nd iron overload in alcoholic cirrhosis
20	no mutations responsible	172.5	83.1	2 nd iron overload with iron supplement
Subtotal from Pt.1 to 10 (Mean±SD)		7.4±5.8	5.2±5.9	
Subtotal from Pt.11 to 20 (Mean±SD)		138.6±62.6	82.1±41.1	
Total (Mean±SD)		73.0±80.0	43.7±48.7	

- *¹ The 745 G>C in *HJV* predicts D249H in HJV protein.
- *² The 1469T>G in *TFR2* predicts L490R in TFR2 protein.
- *³ The 1100T>G in *TFR2* predicts L367R in TFR2 protein.
- *⁴ The 845G>A in *HFE* predicts C282Y in HFE protein.
- *⁵ The 2630G>A in *Cp* predicts W858ter in Cp protein.
- *⁶ The 1467A>C in *SLC40A1* predicts R489S in ferroportin.
- *⁷ The 470A>C in *SLC40A1* predicts D175A in ferroportin.

CRF; chronic renal failure

CHC; chronic hepatitis C

DM; diabetes mellitus

RA; rheumatoid arthritis

Figure 1. Relationships between serum hepcidin-25 and ferritin levels of patients at entry.

Patients with ferroportin disease and secondary iron overload (indicated by closed circles)

showed high hepcidin-25 levels, whereas patients with hemochromatosis and

aceruloplasminemia (indicated by open circles) demonstrated low serum hepcidin-25,

irrespective of high serum ferritin levels. The figure indicates that patients with iron overload

syndromes are clearly divisible into high and low hepcidin groups. However, any correlations are

not observed between serum hepcidin-25 level (y) and ferritin level (x) in the high hepcidin

group ($y = 0.013x + 108$, $r = 0.46$), nor in the low hepcidin group.

Figure 2. Reduction of serum hepcidin-25 levels after phlebotomy.

Two patients each in the low hepcidin and high hepcidin groups responded similarly to


phlebotomy treatment, but differ in serum hepcidin-25 levels. Serum hepcidin-25 levels are low


in patients with hemochromatosis (Cases 3, 5) but high in patients with secondary iron overload

syndromes (Cases 18, 20). Serum ferritin level is indicated in parentheses as ng/mL.

Figure 3. A proposed differential diagnosis of iron overloads syndromes.

Serum hepcidin levels provide a guideline for the genetic study of iron overload syndromes. The first step in differential diagnosis might be to divide the patients into 2 groups with low and high serum hepcidin-25 levels, respectively. The low hepcidin group includes patients with hemochromatosis and a rare aceruloplasminemia, while the high hepcidin group consists of patients with ferroportin disease and acquired iron overload syndromes. Determination of serum ceruloplasmin might be needed before a genetic study of hemochromatosis. Aceruloplasminemia may be suspected from specific clinical features and direct determination of serum ceruloplasmin before hepcidin measurement. In patients with hyperhepcidinemia, genetic analysis for *SLC40A1* is needed before the final diagnosis for secondary iron overload syndromes. The primary target gene in Caucasian hemochromatosis is *HFE*, whereas in non-Caucasians it is *TFR2*.





Iron Overload Syndrome
(Two Times Normal Serum Ferritin)

(measure serum hepcidin 25)

High Hepcidin

Low Hepcidin

Aceruloplasminemia

(measure serum ceruloplasmin)

Non-Aceruloplasminemia

Aceruloplasminemia

Non Caucasian

Caucasian

TFR2, HJV, HAMP, HFE, etc.

HFE, TFR2, HJV, HAMP, etc.

CP

Gene
Analysis

SLC40A1

2nd Iron Overload
Syndrome

Ferroportin
Disease

TFR2-Hemochromatosis, etc.

HFE-Hemochromatosis, etc.

Aceruloplasminemia

